Rebekah Fontenot
Foot & Ankle Surgery · Houston, TXNPI 1457796617
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.8% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Stryker at 33.4% of the total. Reporting peaked in 2021 at $998 and has fallen 96.2% since, to $38 in 2025. That places this record below the midpoint for foot & ankle surgery clinicians in TX, where the typical reported total is $3,901.
Across 75 payments — averaging $32.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Stryker$822
- Smith+Nephew$668
- KCI USA, Inc.$353
- Sanara Medtech Inc.$302
- Paragon 28, Inc.$88
- Aroa Biosurgery Incorporated$71
- plus $156 from 7 others
What the payments were for
- Travel & lodging$40%
- Food & beverage$2,457100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Stryker | 9 | $822 |
| Smith+Nephew | 48 | $668 |
| KCI USA, Inc. | 5 | $353 |
| Sanara Medtech Inc. | 2 | $302 |
| Paragon 28, Inc. | 1 | $88 |
| Aroa Biosurgery Incorporated | 3 | $71 |
| Wound Management Technologies, Inc | 1 | $39 |
| Convatec Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
| Misonix Inc | 1 | $21 |
| Osiris Therapeutics Inc. | 1 | $21 |
| Biom'up France SAS | 1 | $15 |
| Kerecis Limited | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CellerateRx$302
- FIXOS$171
- ALLOWRAP$171
- HOFFMANN$170
- VARIAX$166
- PREVENA$123
- VAC VERAFLO$123
- REGRANEX$123
- SNAP$117
How this compares
$2,461 in reported general payments places this provider in the 35th percentile of 684 foot & ankle surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Ammonium Lactate | 57 | $956 |
| Ketoconazole | 45 | $732 |
| Nystatin | 60 | $495 |
| Piroxicam | 13 | $266 |
| Doxycycline Monohydrate | 12 | $104 |
| Terbinafine Hcl | 11 | $67 |
| Gabapentin | 13 | $39 |
| Triamcinolone Acetonide | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other foot & ankle surgery in Houston
- Kevin VarnerHouston$1.1M
- Sherman NaglerHouston$602K
- Abdul NurudeenHouston$404K
- Orlando RiveraHouston$384K
- Brian LepowHouston$309K
- Yueh LeeHouston$95K
- William GranberryHouston$84K
- Nathaniel AlabiHouston$71K
- Jorge MatukHouston$45K
- William McGarveyKaty$3.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.